Condition 101 content is not available at this time, but we are continually updating the site. Please check back.

However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.

  • Condition: Non Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
  • Journal: Scientific reports
  • Treatment Used: Switching Between Rituximab Biosimilars
  • Number of Patients: 83
  • Published —
This study evaluated the safety of switching between references and rituximab biosimilars in patients with non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL).
Clinical Trial
  • Status: Not yet recruiting
  • Phase: Phase 2
  • Intervention Type: Biological, Drug
  • Participants: 63
  • Start Date: December 31, 2021
A Phase 2 Trial of the Combination of Polatuzumab Vedotin, Venetoclax and Rituximab and Hyaluronidase Human for Relapsed and Refractory Mantle Cell Lymphoma
Clinical Trial
  • Status: Not yet recruiting
  • Phase: Phase 2
  • Intervention Type: Procedure, Device, Drug
  • Participants: 200
  • Start Date: December 1, 2021
A Phase II Trial of CD34+ Enriched Transplants From HLA-Compatible Related or Unrelated Donors for Treatment of Patients With Hematologic Malignancies